2022 - PRESS RELEASES
- Hits: 744
Notice: Undefined property: stdClass::$align in /home/betaengsarco/public_html/templates/yootheme_sidebar/templates/article.php on line 74
2021 - PRESS RELEASES
Notice: Undefined property: stdClass::$align in /home/betaengsarco/public_html/templates/yootheme_sidebar/templates/article.php on line 98
#MDA2021 - LGMD2E Gene Therapy SRP-9003 Shows Benefits After 2 Years - Muscular Dystrophy News Today - March 22 2021
Here's Why Sarepta Therapeutics Lost Support on Wall Street - The Motley Fool - January 10th 2021
- Hits: 2089
2019 - PRESS RELEASES
Myonexus Therapeutics recieves orphan drug designation for Myo-102 - Myonexus January 2nd 2019
Myonexus Therapeutics announces accelerated acquisition by Sarepta Therapeutics. - 2019
Clinical Update: Myo-101 For LGMD Type 2E Business update: Myonexus Acquisition - Sarepta - february 27 2019
Distrofia dei cingoli, Sarepta decide di acquisire Myonexus - Osservatorio Malattie Rare - march 12 2019
Distrofia dei cingoli 2E, primi risultati clinici favorevoli per la terapia genica - Osservatorio Malattie Rare OMAR - April 12 2019
How an Ohio Kids hospital Quitly Became Groung Zero for Gene Therapy - Xconomy - april 15 2019
Gene Delivery for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) by Isolated Limb Infusion - PubMed.gov - July 2019
La terapia genica SRP-9003 mostra risultati molto incoraggianti a 9 mesi nella distrofia dei cingoli - Sarepta Reports - October 9 2019
Distrofia dei cingoli 2E, nuovi risultati positivi per la terapia genica SRP-9003 - Osservatorio Malattie Rare OMAR - October 22 2019
- Hits: 1806
2020 - PRESS RELEASES
Genethon's First Lgmd Biotech - Afm-Telethon - October 28th 2020
Chris Calabrese on His Journey to Become a Filmmaker Despite His Disease – Los Angeles Wire – October 23th 2020
Chris Calabrese Defies Disease and Produces Quality Films – New York Weekly – October 22nd 2020
Sarepta Therapeutics investigational gene therapy SRP-9003 treatment of Limb Girdle Muscular Dystrophy type 2E - September 28th 2020
SRP-9003 Gene Therapy for LGMD2E Shows Benefit after 1 year - Muscular Dystrophy News Today - June 9th 2020
New data gives hope for Limb Girdle Muscular Dystrophy gene therapy - Patient Worthy - June 17th 2020
Owen Steckler – CsiNewsNow - Sunday June 28, 2020
- Hits: 2242
2018 - PRESS RELEASES
First Duchenne Patient Dosed in Microdystrophin Gene Therapy! - January 10th 2018
Young Boy Becomes First DMD Patient to Receive Investigational Systemic Microdystrophin Gene Therapy - January 19th 2018
MDA Clinical Conference Keynote Adress by Dr. Jerry Mendell - March 2018
How Myonexus Therapeutics is developing the first treatment for Limb Girdle Muscular Dystrophies - March 29th 2018
Myonexus Therapeutics receives FDA orphan drug designation for LGMD type 2E treatment
Pioneering, corrective gene therapies have potential to transform quality of life April 2018
Limb Girdle Muscular Dystrophy Type 2E Recruitment Study - Pubmed.gov - April 10th 2018
Clinical Research Forum Top Ten Clinical Research Achivement Awards - April 17th 2018
Myonexus Therapeutics receives FDA Rare Pediatric Disease Designation May 2018
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D (LGMD2D) – PubMed.gov - June 2018
Positive preliminary results from the first three children dosed in phase 1/2A gene Therapy micro-dystrophin trial – Parent Project - June 19th 2018
MDA Funds Creation of Limb-Girdle Muscular Dystrophy Clinical Research Network to Speed Therapy Development - July 27th 2018
Myonexus Therapeutics announced the initiation of a trial for the first-ever Gene Therapy for Beta-Sarcoglycanopathy - 2018
Atrofia Muscolare Spinale: a luglio avvio in Italia sperimentazione di terapia genica.
Our vision for the future of Precision Genetic Medicine - Sarepta Therapeutics 2018 R&D Day
Clinical Update: Micro-dystrophin Study-101 – Sarepta - 2018
- Hits: 1863